The Ballad of TIGIT | Hacker News
TL;DR AI
2 min readKey summary
A Hacker News thread debated how much capital should be committed to studying TIGIT as a drug target.
The core question was whether biotech should run multiple parallel trials on promising targets or move slowly and learn incrementally.
Supporters of the faster approach argued that earlier answers can save more lives, even if it costs more upfront.
The discussion highlights a broader tradeoff in clinical research: speed, cost, and ethics in biotech investment.
Same topic
